Our preliminary observation that the abundance of CD8+ cells in the tumour was negatively correlated with SM loss during therapy suggests, but does not prove, that a strong CD8+ T cell antitumour response may protect against muscle catabolism by reducing tumour burden and consequently diminishing tumour‐derived catabolic signals. This evidence concerns the gene CD8A and neoplasm.